Charcot-Marie Tooth disease

View All

Pharma News for Kyverna, Annovis, Astellas, FibroGen
FDA Fast Track Status to Kyverna’s KYV-101; Annovis’s Phase III Study for Buntanetap; Gilteritinib Demonstrated Benefit in AML Patients; FDA Orphan Drug Designation to DTx Pharma’s DTx-1252; FibroGen’s LELANTOS-1 Phase 3 Clinical Study Result

FDA Grants Fast Track Status to KYV-101 for Refractory Lupus Nephritis Treatment Kyverna Therapeutics announced that the FDA has given Fast Track status to KYV-101, a treatment for patients suffering from resistant lupus nephritis (LN). KYV-101 is an innovative therapy that uses anti-CD19 chimeric antigen recept...

Find More

charcot-marie-tooth-disease-market-cagr-trends-growth-size-share-forecast-therapies-therapy-therapeutics-treatment-drugs
Charcot-Marie-Tooth Disease Market Size Expects Growth Owing to Increasing Prevalence, Influx of Pharma Companies and Novel Therapies

Charcot-Marie-Tooth (CMT) disease is a rare, chronic and sensory neuropathy that causes weakness of the limbs and progresses gradually over time. It can lead to atrophy, sensory loss and complete limb dysfunction. However, rare, the condition is the most common inherited disorder that damages peripheral nerves with...

Find More

Peloton Therapeutics
Neurogene raises $68.5M; AbbVie and Teneobio sign deal; 5AM Ventures nets

Neurogene raises USD 68.5 Million for rare neurological diseases Neurogene netted USD 68.5 million to advance multiple gene therapy programs in its series A round. The idea is to take its major programs into IND-enabling studies for Aspartylglucosaminuria (AGU) and a rare form of Charcot-Marie Tooth disease with...

Find More